TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02979093

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: All women will receive a nasal spray containing a placebo solution.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: All women will receive a nasal spray containing a placebo solution.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional MRI scanning
Description: Study participants undergo two functional MRI scans.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional MRI scanning
Description: Study participants undergo two functional MRI scans.
Study: NCT04133766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Based Nutrition Package (CNBP)
Description: The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
Study: NCT02907541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QI4U learning
Description: Learners will have access to 8 QI methods modules on QI4U

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated learning
Description: Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QI4U and Facilitated learning
Description: Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
Study: NCT03511274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene based educational film
Description: Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
Study: NCT03314818

Intervention type: DEVICE
Intervention: Ultrasound 3D Imaging
Description: Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism.
Study: NCT02718157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between GenePOC PCR and Reference Method
Description: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Study: NCT00622284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo identical to BI 1356 5mg
Description: Placebo tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
Description: Placebo tablets once daily
Study: NCT00666276

Intervention type: DRUG
Intervention: linezolid (Zyvox)
Description: Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration.
Study: NCT02725775

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 100% Florida OJ
Study: NCT03464266

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF and DMPA
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Study: NCT02725775

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Equicaloric Orange Drink
Study: NCT04419623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administered by mouth
Study: NCT03464266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neither DMPA nor FTC/TDF
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Study: NCT03582579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in Virtual Reality
Description: Action Video Game Based Training in Virtual Reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in Virtual Reality
Description: Action Video Game Based Training in Virtual Reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in Virtual Reality
Description: Action Video Game Based Training in Virtual Reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on a computer screen
Description: Action Video Game Based Training on a computer screen
Study: NCT01677988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemotherapy
Description: 1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: 1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies
Study: NCT00499837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Study: NCT00665444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
Study: NCT00101010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg, SC daily, start 24 hours after chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SC one time (24 hours after chemotherapy)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 IVPB on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin hydrochloride
Description: 40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m\^2 oral days 1 - 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: 2 mg IV, day 1
Study: NCT02928874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: % COMPX (low ED vs. high ED preload)
Study: NCT00622284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: 5mg, once daily in the morning for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
Study: NCT00087607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg/day po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b (PEG-Intron)
Description: 1.5 micrograms/kg sc weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000/1200mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly
Study: NCT00916942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsaicin 8%
Description: High concentration capsaicin 8% dermal patch applied for one hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Description: Pre-treatment for NGX-4010
Study: NCT00868608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (CMC-544)
Description: Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
Study: NCT01460004

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: patella knee strap
Description: infra patella strap 100% cotton pressure is exerted immediately under the patella
Study: NCT01738542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiaggregant therapy
Description: AAS 100mg/d or Clopidogrel 75mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiaggregant therapy
Description: AAS 100mg/d or Clopidogrel 75mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Study: NCT03652597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: Subjects receive TMS on several cortical brain locations, while recording the heart rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: Subjects receive TMS on several cortical brain locations, while recording the heart rate.
Study: NCT03996733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demo Video
Description: Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demo Video
Description: Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UltrasoundImaging
Description: Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UltrasoundImaging
Description: Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ModelTraining
Description: Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy.
Study: NCT02184481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Study: NCT03209661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette
Description: E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine 0%
Description: E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
Study: NCT03482167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niagen®
Description: 250 mg capsules (4 capsules daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01230892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 10 mg PO qday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: 100 mg PO qday
Study: NCT02695940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 124249 ointment 30 mg/g
Study: NCT03209661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Menthol Inhalant Product
Description: Menthol inhaler will be administered to determine the effects on vascular function.
Study: NCT02695940

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LEO 124249 ointment vehicle
Study: NCT00759434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery - Saphenofemoral ligation, saphenous strip and avulsions
Description: Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLT
Description: Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
Study: NCT01321281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AquaCal
Description: AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AquaPT
Description: AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
Study: NCT02505152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic intrahepatic portosystemic shunt
Description: Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
Study: NCT02447926

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Leukapheresis
Description: Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours.
Study: NCT00706992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-MART-1 vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-MART-1 vaccine
Description: Given subcutaneously
Study: NCT01253408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match study drug; taken orally with water twice per day for two days.
Study: NCT01086761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.
Study: NCT00706992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-MART-1 vaccine
Description: Given subcutaneously
Study: NCT01086761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.
Study: NCT00080470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bion
Description: battery powered microstimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bion
Description: battery powered microstimulator
Study: NCT03147560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV+ bOPV+ bOPV
Description: Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV + Sabin IPV + bOPV
Description: Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
Study: NCT00706992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L) peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L) peptide vaccine
Description: Given subcutaneously
Study: NCT03147560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV + Sabin IPV + Sabin IPV
Description: Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
Study: NCT02940925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug: Taxol,cisplatin and capecitabine
Description: Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Cisplatin and 5-Fluorouracil
Description: Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.